<unk>  is an anorectic and hypolipidemic agent that is structurally related to fenfluramine patented and manufactured by a French pharmaceutical company Servier. Two clinical studies have shown it may improve glycemic control and decrease insulin resistance in people with poorly controlled type 2 diabetes. However, Servier is suspected of having marketed Mediator<unk>  at odds with the drug's medical properties.
Benfluorex
Cloricromen
Domiphen
Degarelix
Zipeprol
Ospemifene
Clobenzorex
Maralixibat